Femasys Inc. (NASDAQ:FEMY) Short Interest Update

Femasys Inc. (NASDAQ:FEMY) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 776,900 shares, a decline of 6.9% from the May 31st total of 834,700 shares. Based on an average daily volume of 277,000 shares, the days-to-cover ratio is presently 2.8 days. Currently, 3.8% of the company’s shares are short sold.

Femasys Stock Down 5.1 %

Femasys stock traded down $0.06 during midday trading on Tuesday, reaching $1.11. The stock had a trading volume of 82,783 shares, compared to its average volume of 465,503. Femasys has a 12 month low of $0.25 and a 12 month high of $4.75. The company has a market capitalization of $24.66 million, a P/E ratio of -1.32 and a beta of -2.81. The company has a fifty day moving average price of $1.20 and a two-hundred day moving average price of $1.26. The company has a current ratio of 8.43, a quick ratio of 8.02 and a debt-to-equity ratio of 0.29.

Femasys (NASDAQ:FEMY) last issued its earnings results on Thursday, May 9th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.05. Femasys had a negative return on equity of 104.06% and a negative net margin of 1,420.59%. The business had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.30 million. As a group, equities analysts expect that Femasys will post -0.72 EPS for the current fiscal year.

Institutional Trading of Femasys

A hedge fund recently raised its stake in Femasys stock. Clear Creek Financial Management LLC grew its stake in shares of Femasys Inc. (NASDAQ:FEMY) by 30.6% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 309,274 shares of the company’s stock after purchasing an additional 72,505 shares during the period. Clear Creek Financial Management LLC owned about 1.40% of Femasys worth $479,000 as of its most recent filing with the SEC. 65.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on FEMY. HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Femasys in a research note on Thursday, June 20th. Jonestrading boosted their price objective on Femasys from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, March 20th. Finally, Chardan Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Femasys in a research note on Monday, April 1st.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.